Cargando…

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

BACKGROUND: Modifications of FOLFIRINOX are widely used despite the absence of prospective data validating efficacy in metastatic disease (metastatic pancreatic cancer (MPC)) or locally advanced pancreatic cancer (LAPC). We conducted a multicentre phase II study of modified FOLFIRINOX in advanced pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stein, Stacey M, James, Edward S, Deng, Yanhong, Cong, Xiangyu, Kortmansky, Jeremy S, Li, Jia, Staugaard, Carol, Indukala, Doddamane, Boustani, Ann Marie, Patel, Vatsal, Cha, Charles H, Salem, Ronald R, Chang, Bryan, Hochster, Howard S, Lacy, Jill
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984865/ https://www.ncbi.nlm.nih.gov/pubmed/27022826 http://dx.doi.org/10.1038/bjc.2016.45

Ejemplares similares

Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity
por: Zhang, Yue, et al.
Publicado: (2015)

Targeted Radionuclide Therapy
por: Ersahin, Devrim, et al.
Publicado: (2011)

Genomic mutations and histopathologic biomarkers in Y(90) radioembolization for chemorefractory colorectal liver metastases
por: Dendy, Meaghan S., et al.
Publicado: (2018)

Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis
por: Miccio, Joseph A., et al.
Publicado: (2020)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
por: Zhang, Beilei, et al.
Publicado: (2021)

Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
por: Peters, Gabrielle W., et al.
Publicado: (2023)

Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
por: Cecchini, Michael, et al.
Publicado: (2023)

Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?
por: Fernandes, Gustavo dos Santos, et al.
Publicado: (2019)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)

Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer
por: Randrian, Violaine, et al.
Publicado: (2022)

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
por: Chen, Kuei-Ting, et al.
Publicado: (2023)

Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer
por: Patel, Kishan K., et al.
Publicado: (2021)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
por: Adenis, Antoine, et al.
Publicado: (2021)

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019)

Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy
por: Erstad, Derek J., et al.
Publicado: (2018)

A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease
por: Stahl, John M, et al.
Publicado: (2017)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study
por: Rombouts, SJ, et al.
Publicado: (2016)

Pancreatic cancer and FOLFIRINOX: a new era and new questions
por: Marsh, Robert De W, et al.
Publicado: (2015)

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
por: Guion-Dusserre, Jean-Florian, et al.
Publicado: (2016)

Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
por: Sakr, Amr, et al.
Publicado: (2020)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX
por: Inoue, Naonori, et al.
Publicado: (2021)

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2019)

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience
por: Chllamma, Muralidharan K, et al.
Publicado: (2016)

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study
por: Suker, Mustafa, et al.
Publicado: (2018)

FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
por: Lamarca, Angela, et al.
Publicado: (2020)

FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma
por: Vary, Antonin, et al.
Publicado: (2021)

Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer
por: Li, Xujia, et al.
Publicado: (2023)

Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI
por: Nikolaou, Christos, et al.
Publicado: (2015)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020)

Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study
por: Sharma, Atul, et al.
Publicado: (2021)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma
por: Lellouche, Lisa, et al.
Publicado: (2023)

Técnicas estructuradas y orientadas a objetos : una introducción utilizando C++
por: Staugaard, Andrew C.
Publicado: (1998)

6809 microcomputer programming and interfacing with experiments
por: Staugaard, Andrew C
Publicado: (1981)

Cannot write session to /tmp/vufind_sessions/sess_7re1a0smp55fb3trhkuo7kac2q